

FOR IMMEDIATE RELEASE

Remy Biosciences: Embarking on a Global Healthcare Revolution with Strategic Licensing Agreement with Datarocx Inc.

[Santa Ana, California – April 8, 2024] — Remy Biosciences, a trailblazing biotechnology company committed to advancing healthcare solutions worldwide, proudly announces a transformative licensing agreement with Datarocx Inc., a recognized global leader with a diverse portfolio spanning Data Center, Telecommunications, and Solar industries. This collaboration marks a significant milestone for both companies and holds immense promise for patients globally.

Remy Biosciences specializes in developing innovative drug delivery systems, including the groundbreaking Remy Biosciences Biodermal Technology™ patches and sublingual pills, aimed at improving health outcomes. With a mission to empower worldwide health solutions through strategic expansion and technological leadership, Remy is dedicated to delivering impactful healthcare innovations.

Datarocx Inc. stands as a pillar of innovation, boasting substantial achievements and global partnerships. Their credibility stands out with established agreements poised to unlock millions in potential funding from both public and private sources, paving the way for significant future growth and innovation.

The strategic licensing agreement grants Datarocx exclusive rights to utilize Remy Biosciences' proprietary technology for the development, manufacture, and sale of Biodermal patches and sublingual pills in key territories spanning Pakistan, India, the Middle East, and North Africa. These regions collectively represent nearly 50% of the global population and are among the fastest-growing economic regions globally.

The agreement, set for a term of ten years with provisions for automatic renewal, reflects the long-term commitment of both parties to drive sustained growth and address evolving patient needs.

The partnership has garnered broad-based support from governmental agencies, investors, clinicians, and distributors, indicating strong market readiness for healthcare solutions. With a future defined by collaboration and impact, Remy Biosciences and Datarocx Inc. are committed to leveraging their collective strengths to enhance global health access and care.

"This alliance with Datarocx Inc. represents a pivotal moment in Remy Biosciences' journey," said Justin Brown, Chief Executive Officer of Remy Biosciences. "Together, we are uniquely positioned to make a lasting difference in the international healthcare landscape, improving outcomes for patients worldwide."

"We are excited to partner with Remy Biosciences to contribute toward better patient outcomes and address critical healthcare issues in various international markets. This agreement with Remy Biosciences marks an exciting opportunity for Datarocx Group of companies, said Agha Babar Saeed, CEO of Datarocx.

Embarking on this transformative journey, Remy Biosciences and Datarocx Inc. are committed to delivering innovative healthcare solutions that make a meaningful impact on global health.

For more information:

Brent Cahill
Executive Vice President
(949) 444-1358
brentc@remybiosciences.com